HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem Posts Strong Q1 On Selsun Blue, ACT, Cortisone

This article was originally published in The Rose Sheet

Executive Summary

The success of Selsun Blue Naturals is leading a revival of the Selsun dandruff franchise, fueling its strongest performance in six periods, Chattem said during an April 8 first-quarter earnings call

You may also be interested in...



Chattem Can’t Say No To Wal-Mart; J&J Brands Continue To Surprise

Chattem does not have any single strategy for success, but the company has only one answer to requests from the world's largest mass marketer

Chattem Can’t Say No To Wal-Mart; J&J Brands Continue To Surprise

Chattem does not have any single strategy for success, but the company has only one answer to requests from the world's largest mass marketer

Chattem’s Core Brands Off To Strong Start In Fiscal ’08; Firm Ups Projections

Chattem has up-adjusted its 2008 earnings estimates following a strong start to the year and with high expectations for product initiatives to come

Related Content

UsernamePublicRestriction

Register

RS015356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel